RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsBy the year 2030, the global healthcare budget is estimated to rise to $15 trillion.
Consequently precision medicine will gain prominance in seeking to gain some control over this riding healthcare spend.
This notwithstanding, there’s a huge, and growing, opportunity to digitally disrupt the healthcare space. Despite having no experience in drug discovery or development, tech giants like Amazon, Microsoft, Apple, Alphabet and others are making major investments in health and wellness. They are vying with pharma titans like Pfizer, Merck, GSK and others who, by comparison, only have modest experience in managing, analyzing and extracting utility from zettabytes of digital information. In the future, these two industries will compete for access to patient data and the ability to benefit from it. Whoever is best able to utilize every individual’s digital health record, fed by his or her “data-ome,” will capture significant new profit pools and disrupt existing ones.
Tech giants are searching for ways to establish a leadership position in the quickly evolving healthcare sector. They are using their extraordinarily large cash balances to bolster their internal healthcare R&D budgets as well as investing heavily and aggressively in AI companies, data analytics startups and biotech enterprises.
Stating that cancer and other biological processes are information processing systems, Microsoft launched an extraordinarily ambitious program to “solve” cancer within a decade.